Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Assessment of a Multimodal Analgesia for Enhanced Recovery After Cardiac Surgery

NCT07417462 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2026-02-18
Last updated
2026-07-21

Condition(s) studied

Transversus Thoracic Muscle Plane BlockPecto-intercostal Fascial BlockEnhanced RecoveryCardiac Surgery

Investigational drug(s) / intervention(s)

Pecto-intercostal fascial blockTransversus thoracic muscle plane blockSham (No Treatment)

Pecto-intercostal fascial block: Patients will receive pecto-intercostal fascial block intraoperatively (20 ml of bupivacaine 0.25% + 1 ml dexamethasone 8 mg).

Transversus thoracic muscle plane block: Patients will receive transversus thoracic muscle plane block was performed intraoperatively (20 ml of bupivacaine 0.25% + 1 ml dexamethasone 8 mg).

Sham (No Treatment): Patients will receive bilateral superficial needle puncture at a location like transversus thoracic muscle plane block without any solution injected. Only 25 saline will be injected superficially.

Study summary

This work aims to assess the analgesic efficacies of transversus thoracic muscle plane block (TTPB) and transversus thoracic muscle plane block (TTPB) for open cardiac surgeries

Eligibility

Sex
ALL
Min age
40 Years
Max age
60 Years
Healthy volunteers
No
Inclusion Criteria: * Age from 40 to 60 years. * Both sexes. * American Society of Anesthesiology (ASA) physical status II-III. * Body mass index (BMI) \< 35 kg/m2. * Underwent cardiac surgery (coronary artery bypass graft surgery with median sternotomy). Exclusion Criteria: * Valve replacement procedures. * Emergency operations. * Redo surgeries. * Minimally invasive approaches. * The presence of psychiatric disorders. * Cognitive impairment preventing accurate assessment using the verbal numerical rating scale (NRS). * Known hypersensitivity or a history of allergy to local anesthetics. * Had severe major organ dysfunction. * Left ventricular ejection fraction below 30%. * Pregnancy or breastfeeding.

Primary outcome measure(s)

  • Total amount analgesic requirement — 24 hours postoperatively
    In cases where rescue analgesia is required \[numerical rating scale (NRS) ≥4\], intravenous Nalbuphine 0.1 mg/kg will be given.

Trial sites (1)

FacilityCityRegionStatus
Assiut University Asyut Egypt Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07417462 on ClinicalTrials.gov ↗ ← All trials in Egypt